DexCom Stock Surges on Q2 Earnings Beat and Raised Guidance

Shares of DexCom (DXCM) surged more than 11% in morning trading after the medical device company reported second-quarter 2026 financial results that exceeded Wall Street expectations and raised its full-year outlook.

Earnings Beat and Raised Outlook

DexCom announced second-quarter adjusted earnings per share of $0.70, surpassing the consensus analyst estimate of $0.61. The company posted revenue of $1.31 billion, a 13% increase year-over-year, which also beat the forecast of $1.29 billion.

Gross margin improved significantly to 64.1%, up from 60.1% in the same period last year. The company attributed this expansion to manufacturing efficiencies and the ongoing rollout of its G7 15-day sensor. Bolstered by the strong performance, DexCom raised its full-year 2026 revenue guidance to a range of $5.18 billion to $5.25 billion, which implies annual growth of 11% to 13%.

Market Reaction and Analyst Confidence

The strong report sent DexCom shares to a new 52-week high of $84.70 during the session. The rally was notable as it occurred while major U.S. indices were trading modestly lower, indicating the move was driven by company-specific catalysts rather than a broader market tailwind.

Ad

Following the release, several Wall Street firms reiterated their confidence in the stock. Analysts at BTIG maintained a Buy rating and increased their price target to $90.00 from $80.00, while Benchmark also lifted its target to $82 from $77.

Financial Health and Growth Initiatives

DexCom's financial position remains robust, ending the quarter with approximately $1.9 billion in cash. The company generated over $600 million in free cash flow in the first half of 2026, more than doubling the prior-year period's figure. DexCom also repurchased about $600 million of its stock in the second quarter as part of its $1 billion share-repurchase authorization for 2026.

Looking ahead, the company highlighted several growth drivers, including expanding access for non-insulin Type 2 diabetes patients and the recent launch of its DexCom Flex sensor in Germany. DexCom also provided an update on its next-generation G8 platform, a multi-analyte sensor targeted for late 2027 or early 2028.